Oncology-focused biotechnology
Vasi Pharma LLC is advancing innovative oncology therapeutics through biology-led discovery, medicinal chemistry, translational science, and AI-enabled drug discovery.
Our programs are designed to address high unmet medical needs across difficult-to-treat cancers, with an emphasis on therapeutic resistance, aggressive tumor biology, and patient impact.
Therapeutic programs centered on high unmet need cancers.
Biology-led discovery supported by medicinal chemistry and translational planning.
Focused on diseases where better treatment options are urgently needed.
Built for scientific collaborations and non-dilutive development pathways.
About Vasi Pharma
Vasi Pharma LLC is an emerging biotechnology company focused on discovering and developing therapeutic candidates for cancer. Our work bridges molecular innovation, disease biology, medicinal chemistry, and translational research to advance programs with strong scientific rationale.
We prioritize rigorous experimental validation, collaborative science, and development strategies that can support future non-dilutive funding, strategic partnerships, and preclinical advancement.
Our Mission
To integrate biology, chemistry, translational science, and AI-enabled approaches to develop innovative cancer therapeutics with speed, precision, and scientific discipline.
Our Vision
To advance a differentiated therapeutic portfolio addressing urgent and underserved medical needs through rigorous science, strategic collaborations, and responsible development.
Pipeline
Vasi Pharma is advancing investigational oncology programs across high unmet medical need cancers. Program details are selectively disclosed to qualified scientific, funding, and strategic partners under appropriate confidentiality protections.
Why These Cancers Matter
Vasi Pharma focuses on cancer types where aggressive disease biology, resistance, relapse, and limited treatment options continue to create significant burden for patients and families.
Triple-negative breast cancer is an aggressive form of breast cancer with fewer targeted treatment options than receptor-positive disease. Many patients face high recurrence risk, metastatic progression, and treatment resistance.
Prostate cancer is common among men, and advanced disease can become resistant to standard therapies. New approaches are needed for patients whose disease progresses despite current treatment options.
Kidney cancer, including renal cell carcinoma, can be difficult to treat in advanced stages and may develop resistance to existing therapies. Translational renal oncology remains an important area of need.
Leukemia and brain cancers represent complex and difficult-to-treat malignancies. These diseases can involve relapse, resistance, barriers to drug delivery, and substantial patient burden.
Scientific Approach
Our discovery strategy is designed to move promising concepts from biological rationale toward decision-focused preclinical milestones.
Programs begin with disease mechanisms, tumor vulnerabilities, and translational relevance.
Small-molecule discovery and optimization strategies support portfolio development.
Computational approaches support hypothesis generation, candidate prioritization, and efficient decision-making.
Programs are evaluated with emphasis on biological validation, therapeutic potential, and future clinical relevance.
Collaborations & Funding
Vasi Pharma welcomes scientific collaborations, translational partnerships, and discussions related to non-dilutive funding opportunities supporting therapeutic innovation.
We are interested in opportunities aligned with NIH, NCI, DoD/CDMRP, NSF, and other translational research programs that support high-impact therapeutic development.
We seek disease biology, translational oncology, model development, and preclinical validation collaborations with aligned scientific investigators.
We welcome conversations with partners interested in oncology therapeutics, small-molecule discovery, program advancement, and co-development.
Core Values
Rigorous and reproducible science guides every decision.
We move quickly while maintaining quality, rigor, and patient focus.
Breakthroughs happen when disciplines and institutions converge.
We encourage bold thinking and challenge assumptions.
Everything we do is ultimately about improving lives.
Contact
For scientific collaborations, funding discussions, or strategic partnerships: